EE153 Budget Impact Analysis of Introducing Mobocertinib for Locally Advanced or Metastatic Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small-Cell Lung Cancer in the United States from the Payer Perspective
Abstract
Authors
LG Hernandez M Young